Compare AstraZeneca plc (AZN) vs ON Holding AG (ONON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs ON Holding AG — how do they compare? AstraZeneca plc trades at $166.76 (market cap $253.13B), while ON Holding AG trades at $37.74 (market cap $12.58B). The key difference: AstraZeneca plc is far larger — about 20.1× ON Holding AG's market cap, and AstraZeneca plc pays a 1.92% dividend while ON Holding AG pays none. Which is the better fit depends on your goals.
| AZN | ONON | |
|---|---|---|
Market Cap | $253.13B | $12.58B |
Sector | Health | Technology |
52-Week High | $209.48 | $54.24 |
52-Week Low | $137.44 | $31.88 |
Enterprise Value | $279.37B | $11.90B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
ONON trades at $37.92, down 1.61% today, with a bullish technical trend and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $0.47 exceeding expectations. Revenue reached $3.01B in 2025, with gross margins at 63.88% and net income of $203.70M. Analyst sentiment is overwhelmingly positive, with 76.92% recommending Buy and a consensus price target of $47.33.
Outlook remains favorable given robust growth and margin expansion, but risks include high valuation multiples and competitive pressures. The stock offers upside potential if execution continues, though investors should monitor earnings sustainability and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →
